All In MedTech

Device Trial Radar · NCT05396495

Safety and Feasibility of the NeurolyserXR for Sacroiliac Joint Pain

Safety and Initial Feasibility of Using the Neurolyser XR Device for the Treatment of Sacroiliac Joint Related Low Back Pain

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Sep 24, 2024

Primary completion

May 1, 2027

Study completion Jul 1, 2027

Sponsor

Lead sponsor
FUSMobile Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Sheba Medical Center
First posted
May 31, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pilot study to evaluate the safety and the effectiveness of the Neurolyser XR as a treatment for sacroiliitis

Conditions

  • Sacroiliitis

Interventions

  • NeurolyserXRDevice

    Using the NeurolyserXR to non-invasively ablate the posterior sacral branches enervating the sacroiliac joint

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effectiveness per pain score using numerical rating scale of 0 to 10Time frame: Baseline throughout the follow-up period of six months
  2. Safety per adverse eventsTime frame: Baseline throughout the follow-up period of six months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sheba Medical Center

    Giv‘atayim, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.